Donald Brian Calne
#93,417
Most Influential Person Now
Donald Brian Calne's AcademicInfluence.com Rankings
Donald Brian Calnephilosophy Degrees
Philosophy
#3480
World Rank
#5617
Historical Rank
Logic
#1183
World Rank
#1867
Historical Rank
Donald Brian Calnebiology Degrees
Biology
#4354
World Rank
#6503
Historical Rank
Neuroscience
#456
World Rank
#475
Historical Rank
Download Badge
Philosophy Biology
Donald Brian Calne's Degrees
- PhD Neurophysiology University of British Columbia
Why Is Donald Brian Calne Influential?
(Suggest an Edit or Addition)Donald Brian Calne's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Multiple receptors for dopamine (1979) (3687)
- Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology (2004) (2782)
- Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) (1996) (2382)
- Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease (2001) (933)
- Criteria for diagnosing Parkinson's disease (1992) (656)
- DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS (1986) (653)
- In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease (2000) (558)
- Reaction time in Parkinson's disease. (1981) (538)
- A susceptibility locus for Parkinson's disease maps to chromosome 2p13 (1998) (492)
- AETIOLOGY OF PARKINSON'S DISEASE (1983) (477)
- Manganese neurotoxicity: a review of clinical features, imaging and pathology. (1999) (430)
- Treatment of spasticity with botulinum toxin: A double‐blind study (1990) (416)
- Parkinson's disease in 65 pairs of twins and in a set of quadruplets (1983) (397)
- Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease (1995) (396)
- Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. (2004) (390)
- Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? (1997) (371)
- Manganism and idiopathic parkinsonism (1994) (354)
- Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels (1993) (351)
- Bromocriptine in Parkinsonism (1974) (330)
- Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease (1985) (326)
- Parkinson's disease: a case-control study of occupational and environmental risk factors. (1990) (313)
- Dopamine release in human ventral striatum and expectation of reward (2002) (310)
- Nigrostriatal function in humans studied with positron emission tomography (1989) (305)
- Assessment of Parkinson's Disease (1984) (303)
- DCTN1 mutations in Perry syndrome (2009) (286)
- Manganese intoxication in the rhesus monkey (1996) (261)
- ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AND MOTONEURONE DISEASE: ABIOTROPIC INTERACTION BETWEEN AGEING AND ENVIRONMENT? (1986) (259)
- Autosomal dominant parkinsonism associated with variable synuclein and tau pathology (2004) (258)
- PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. (2005) (257)
- Age‐dependent decline of dopamine D1 receptors in human brain: A PET study (1998) (241)
- Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. (2001) (231)
- Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism (1994) (229)
- Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. (2009) (220)
- Olfactory impairment in Parkinson's disease (1983) (216)
- The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. (2004) (207)
- Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease (2011) (206)
- Progression after chronic manganese exposure (1993) (203)
- Hereditary form of parkinsonism—dementia (1998) (202)
- A Pilot Study on the Use of Botulinum Toxin in Spasmodic Torticollis (1985) (190)
- Rapidly progressive autosomal dominant parkinsonism and dementia with pallido‐ponto‐nigral degeneration (1992) (188)
- Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices (1993) (182)
- Treatment of Parkinson's disease. (1993) (175)
- Chronic manganese intoxication. (1989) (175)
- Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover (2001) (167)
- L-Dopa and Parkinsonism (1970) (158)
- Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions (1994) (157)
- Positron emission tomography in manganese intoxication (1989) (156)
- Alzheimer's disease and parkinson's disease: Distinct entities or extremes of a spectrum of neurodegeneration? (1998) (152)
- Clinical observations on the rate of progression of idiopathic parkinsonism. (1994) (150)
- Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis (1990) (149)
- Long-term progression in chronic manganism (1998) (147)
- The metabolism of orally administered l‐DOPA in Parkinsonism (1969) (145)
- Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease. Six-month follow-up with additional 1-year observations. (1997) (144)
- Cerebral glucose metabolism in Parkinson's disease with and without dementia. (1992) (143)
- LONG-TERM TREATMENT OF PARKINSONISM WITH BROMOCRIPTINE (1978) (141)
- A case‐control study of Parkinson's disease in a horticultural region of British Columbia (1994) (140)
- Metabolism of (‐) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit (1982) (140)
- Twin study of Parkinson disease (1981) (139)
- Positron emission tomography and histopathology in Pick's disease (1987) (137)
- Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease. (1979) (136)
- PET studies of parkinsonism associated with mutation in the alpha-synuclein gene. (1999) (136)
- MRI and PET studies of manganese‐intoxicated monkeys (1995) (133)
- Lesions of the putamen and dystonia (1984) (133)
- Treatment of parkinsonism with bromocriptine. (1974) (132)
- Hypotension Caused by L-Dopa (1970) (120)
- Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. (2004) (117)
- Profile of families with parkinsonism‐predominant spinocerebellar ataxia type 2 (SCA2) (2004) (116)
- Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. (1986) (116)
- Presynaptic and postsynaptic striatal dopaminergic function in patients with manganese intoxication (1997) (114)
- Patterns of Asymmetry Do Not Change Over the Course of Idiopathic Parkinsonism (1995) (112)
- Levodopa failure in chronic manganism (1994) (108)
- Western Nebraska Family (Family D) with Autosomal Dominant Parkinsonism (1995) (108)
- X-linked scapuloperoneal syndrome (1972) (108)
- Comparison of pergolide and bromocriptine therapy in parkinsonism (1983) (108)
- Normal aging of the nervous system (1991) (104)
- L-dopa in postencephalitic parkinsonism. (1969) (103)
- Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease) (2004) (99)
- Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with Levodopa (1971) (98)
- BROMOCRIPTINE AND LEVODOPA (WITH OR WITHOUT CARBIDOPA) IN PARKINSONISM (1976) (96)
- Motor nerve conduction velocity in peroneal muscular atrophy: evidence for genetic heterogeneity (1974) (96)
- Considerations in the management of parkinsonism (1978) (95)
- Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning (1993) (95)
- Long‐term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa‐responsive dystonia (1992) (94)
- Is idiopathic parkinsonism the consequence of an event or a process? (1994) (94)
- Aetiology of Parkinsońs disease (1983) (93)
- Positron emission tomographic studies of dopa‐responsive dystonia and early‐onset idiopathic parkinsonism (1993) (93)
- Botulinum toxin A as treatment for drooling saliva in PD (2000) (92)
- Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism (2000) (91)
- Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint (1999) (90)
- Pallidonigral TDP-43 pathology in Perry syndrome. (2009) (89)
- Nigrostriatal dopamine system and motor lateralization (2000) (89)
- Swallowing in Parkinsonism. (1970) (88)
- Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. (1994) (88)
- Hereditary motor and sensory polyneuropathy (peroneal muscular atrophy) * (1974) (86)
- Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism. (1991) (86)
- Deprenyl in Parkinson disease (1981) (85)
- L-dopa in idiopathic parkinsonism. (1969) (85)
- The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic (1992) (84)
- Genetic linkage studies in autosomal dominant parkinsonism: Evaluation of seven candidate genes (1994) (84)
- Cross‐Cultural Cognitive Examination: Validation of a Dementia Screening Instrument for Neuroepidemiological Research (1993) (84)
- Age-dependent decline in motor evoked potential (MEP) amplitude: with a comment on changes in Parkinson's disease. (1991) (83)
- Amyotrophic Lateral Sclerosis, Parkinson’s Disease and Alzheimer’s Disease: Phylogenetic Disorders of the Human Neocortex Sharing Many Characteristics (1992) (83)
- Screening Parkinson's disease: A validated questionnaire of high specificity and sensitivity (1995) (83)
- 18Fluorodeoxyglucose Positron Emission Tomography Studies in Presumed Alzheimer Cases, Including 13 Serial Scans (1990) (82)
- CFS hydroxylase cofactor levels in some neurological diseases. (1980) (81)
- Familial Parkinson's Disease: Possible Role of Environmental Factors (1987) (80)
- IDIOPATHIC PARKINSONISM TREATED WITH BROMOCREPTINE (1975) (80)
- Blink rates in parkinsonism (1982) (79)
- PLEUROPULMONARY CHANGES DURING LONG-TERM BROMOCRIPTINE TREATMENT FOR PARKINSON'S DISEASE (1981) (79)
- Stimulation of the basal nucleus of Meynert in senile dementia of Alzheimer's type. A preliminary report. (1985) (76)
- Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? (1992) (76)
- Bromocriptine. A clinical and pharmacological review. (1980) (76)
- Motor function in the normal aging population: treatment with levodopa. (1985) (75)
- German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia - Longitudinal observations. (1997) (75)
- Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. (2007) (74)
- Vocal cord paralysis in the Shy-Drager syndrome. (1979) (73)
- VMAT2 binding is elevated in dopa‐responsive dystonia: Visualizing empty vesicles by PET (2003) (72)
- Lisuride in parkinsonism (1981) (71)
- SCA-2 presenting as parkinsonism in an Alberta family (2002) (69)
- Parkinsonism induced by solvent abuse (1994) (68)
- Occupational risk factors in Parkinson's disease. (1999) (68)
- The free radical hypothesis in idiopathic parkinsonism: Evidence against it (1992) (67)
- Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations (2000) (67)
- Cerebral Glucose Metabolism in Parkinson’s Disease (1984) (66)
- Reassessment of unilateral pallidotomy in Parkinson's disease. A 2-year follow-up study. (1999) (64)
- Unilateral pallidotomy for reduction of parkinsonian pain. (1999) (63)
- Severe vascular disturbance in a case of familial brain calcinosis (2005) (63)
- Pleuropulmonary disease associated with dopamine agonist therapy (1991) (63)
- The neuromythology of Parkinson's Disease. (2004) (62)
- Studies of parkinsonian movement: 1. Programming and execution of eye movements (1980) (62)
- A mathematical model of pathogenesis in idiopathic parkinsonism. (1994) (61)
- Vibratory sense: a critical review. (1966) (61)
- Botulinum toxin in spasmodic torticollis. (1988) (61)
- The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography. (1991) (60)
- Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study (2001) (59)
- Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. (1999) (58)
- PET studies of cerebral glucose metabolism in idiopathic torticollis (1986) (57)
- Effortful and automatic memory (1984) (57)
- Age‐dependent decline of nigrostriatal dopaminergic function: A positron emission tomographic study of grandparents and their grandchildren (1994) (56)
- Lisuride versus bromocriptine treatment in Parkinson disease (1982) (56)
- Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. (2004) (56)
- Treatment of Dopaminomimetic Psychosis in Parkinson's Disease with Electroconvulsive Therapy (1988) (55)
- SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia (2014) (55)
- Therapeutic Implications in Parkinsonism of m-Tyramine Formation from L-Dopa in Man (1971) (55)
- Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam. (1990) (54)
- Effect of an opiate antagonist on movement disorders. (1978) (54)
- Studies with bromocriptine Part 1. “On‐off” phenomena (1976) (53)
- Action tremor in Parkinson's disease. (1980) (52)
- Parkinsonism: physiology, pharmacology and treatment (1970) (52)
- Dystonia and calcification of the basal ganglia (1985) (51)
- Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography (1998) (51)
- Apomorphine-Induced Changes in Synaptic Dopamine Levels: Positron Emission Tomography Evidence for Presynaptic Inhibition (2001) (51)
- Phenotypic expression of X‐linked dystonia‐parkinsonism (lubag) in two women (1993) (50)
- Is "Parkinson's disease" one disease? (1989) (49)
- Biochemical and fluorodopa positron emission tomographic findings in an asymptomatic carrier of the gene for dopa‐responsive dystonia (1994) (49)
- The cardiovascular effects of bromocriptine in Parkinsonism. (1976) (49)
- The long-term response to levodopa in dopa-responsive dystonia. (2001) (49)
- Transplantation of human sympathetic neurons and adrenal chromaffin cells into parkinsonian monkeys: no reversal of clinical symptoms (1989) (48)
- Late Progression of Post-Encephalitic Parkinson's Syndrome (1988) (48)
- m-Hydroxyphenylacetic Acid Formation from L-Dopa in Man: Suppression by Neomycin (1969) (48)
- PET studies of parkinsonism associated with mutation in the α-synuclein gene (1999) (48)
- Tardive dyskinesia treated with pimozide (1975) (48)
- Transamination is a Major Pathway of L-Dopa Metabolism following Peripheral Decarboxylase Inhibition (1974) (47)
- Prolactin secretion in Parkinson disease (1981) (46)
- Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions (2003) (46)
- The natural history of neurological manganism over 18 years. (2007) (46)
- Daytime somnolence in patients with Parkinson's disease. (2001) (46)
- Secondary dystonia. (1988) (45)
- Parkinsonism and aging (1989) (45)
- The effect of dietary protein on the efficacy of L‐dopa (1989) (45)
- Optimal Indices for Testing Parkinsonian Rigidity (1989) (44)
- Determination of an Occupational Exposure Guideline for Manganese Using the Benchmark Method (2003) (44)
- Long term outcome of unilateral pallidotomy: follow up of 15 patients for 3 years (2000) (44)
- Cortical glucose metabolism in parkinson's and alzheimer's disease (1990) (43)
- Studies with bromocriptine (1976) (43)
- A definition of Parkinson's disease. (2005) (43)
- Neurodegenerative 'overlap' syndrome: Clinical and pathological features of Parkinson's disease, motor neuron disease, and Alzheimer's disease. (1995) (42)
- Drugs for the Treatment of Parkinson’s Disease (2011) (42)
- Evidence for environmental causation of Parkinson's disease. (2002) (42)
- Erythromelalgia‐like eruption in parkinsonian patients treated with bromocriptine (1981) (42)
- Supranuclear disturbances of ocular motility in Lytico‐Bodig (1988) (41)
- A retinopathy on Guam with high prevalence in Lytico-Bodig. (1989) (41)
- Clozapine: an antipsychotic agent in Parkinson's disease? (1989) (40)
- Lesions of the putamen (1987) (39)
- “Familial Parkinson's Disease” – A Case-Control Study of Families (1997) (39)
- Action of dopamine on the human iris (1969) (39)
- Reproducibility of the distribution of carbon-11-SCH 23390, a dopamine D1 receptor tracer, in normal subjects. (1998) (39)
- Age and severity of nigrostriatal damage at onset of Parkinson's disease (2003) (38)
- Atenolol vs. propranolol in essential tremor A controlled, quantitative study (1982) (37)
- Lergotrile mesylate: an in vivo dopamine agonist which blocks dopamine receptors in vitro. (1977) (37)
- Treatment of Parkinson's Disease with Sodium Valproate: Clinical, Pharmacological, and Biochemical Observations (1979) (37)
- Non-dystonic causes of torticollis. (1988) (37)
- Local Treatment of Spasmodic Torticollis with Botulinum Toxin (1987) (36)
- (+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM (1985) (36)
- Pallidotomy for tardive dyskinesia (1997) (36)
- A community survey of Parkinson's disease. (1989) (35)
- PATHOPHYSIOLOGY OF MOTOR PERFORMANCE IN PARKINSON'S DISEASE (1979) (35)
- The Relationship Between Alzheimer's Disease, Parkinson's Disease and Motor Neuron Disease (1989) (35)
- Positron emission tomography in progressive supranuclear palsy. (1991) (34)
- Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. (2009) (34)
- Autosomal dominant dystonia-plus with cerebral calcifications (2006) (34)
- Methods for evaluating treatment in Parkinson's disease. (1983) (34)
- Diagnosis and treatment of Parkinson's disease. (1995) (33)
- A double‐blind, placebo‐controlled, dose‐ranging study to investigate the safety and efficacy of CY 208‐243 in patients with Parkinson's disease (1989) (33)
- “On-Off” Phenomena Related to High Plasma Levodopa (1973) (33)
- Within Reason: Rationality and Human Behavior (1999) (32)
- Pathways converging upon Purkinje cells in the frog's cerebellum (1959) (32)
- Studies with bromocriptine Part 2. Double‐blind comparison with levodopa in idiopathic parkinsonism (1976) (32)
- Amyotrophic lateral sclerosis/parkinsonism-dementia complex in southern Guam: is it disappearing? (1991) (31)
- Did Leonardo describe Parkinson's disease? (1989) (31)
- Clustering of Parkinson disease: shared cause or coincidence? (2004) (31)
- A new indirect method for measuring spinal conduction velocity in man. (1984) (31)
- PET Studies of Parkinsonian Patients Treated with Autologous Adrenal Implants (1989) (30)
- Parkinsonism with 'on-off' phenomena. Intravenous treatment with levodopa after major abdominal surgery. (1979) (30)
- Oligoclonal banding in the cerebrospinal fluid of patients with postencephalitic Parkinsonism. (1979) (30)
- The roles of presynaptic function and hepatic drug metabolism in the hypothermic actions of two novel dopaminergic agonists (1977) (30)
- Handbook of dystonia (1995) (29)
- Comparison between lergotrile and bromocriptine in parkinsonism (1978) (29)
- Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. (2001) (29)
- Bromocriptine in Huntington chorea. (1976) (29)
- Pathogenesis of idiopathic parkinsonism. (1993) (29)
- Aging of the Nigrostriatal Pathway in Humans (1987) (29)
- Developments in the pharmacology and therapeutics of parkinsonism (1977) (28)
- The Use of Pet in Parkinsons-Disease (1995) (28)
- Fluorodopa and raclopride PET analysis of patients with Machado-Joseph disease (1997) (28)
- Normal CAG repeat length in the Huntington's disease gene in senile chorea (1994) (28)
- Presynaptic nigrostriatal function in genetically tested asymptomatic relatives from the pallido-ponto-nigral degeneration family (1996) (28)
- Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson's disease. (2003) (28)
- The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates. (1991) (27)
- Lamotrigine trial in idiopathic parkinsonism (1997) (27)
- Parkinson's disease in twins. (1984) (27)
- Alzheimer's Disease and Related Conditions. (1971) (26)
- Tyrosine hydroxylase cofactor (tetrahydrobiopterin) in parkinsonism. (1984) (26)
- Suppression of Experimental Allergic Encephalomyelitis by Cytotoxic Drugs (1963) (26)
- The Age of Onset of Parkinson's Disease: Etiological Implications (1986) (25)
- Cardiovascular reflexes in Parkinsonism. (1971) (25)
- The encephalopathic action of five-carbon-atom fatty acids in the rabbit. (1976) (25)
- Nomifensine in parkinsonism. (1976) (25)
- Parkinsonism. Clinical and neuropharmacologic aspects. (1978) (25)
- Familial and sporadic Parkinson's disease usually display the same clinical features. (2003) (24)
- Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase. (1972) (23)
- Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation (2007) (23)
- Occupational Risk Factors in Parkinson’s Disease (1999) (23)
- L‐dopa decarboxylation in chronically treated patients (1984) (23)
- PET scanning in dystonia. (1988) (23)
- Familial aggregation of Parkinson's disease. (2001) (22)
- Experimental therapeutics of movement disorders. (1983) (22)
- Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA. (1997) (21)
- Dopamine Agonists in Parkinson’s Disease (1984) (21)
- Progress in the treatment of Parkinsonism (1973) (21)
- Isolated involvement of substantia nigra in acute transient parkinsonism: MRI and PET observations. (1995) (21)
- HYPOTHERMIC ACTION OF BROMOCRIPTINE (1975) (21)
- Site-specific invasion of the basal ganglia by Nocardia asteroides GUH-2 (2000) (20)
- The use of PET in Parkinson's disease. (1995) (20)
- Electromyographic studies of tremor using an averaging computer. (1969) (20)
- Selegiline in Parkinson's disease (1995) (20)
- Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia. (1997) (19)
- Parkinsonism with Neuroacanthocytosis (1990) (19)
- Experiences with a new ergoline (CF 25–397) in parkinsonism (1977) (19)
- Progress in Parkinson's disease. (1984) (19)
- The action of L(-)-dopa on baroreflexes in Parkinsonism. (1972) (19)
- An ergot derivative in the treatment of Parkinson's disease. (1976) (19)
- Parkinsonism—Physiology and Pharmacology (1971) (18)
- Speculations on the etiology of Parkinson's disease. (1984) (18)
- Cardinal Features of Early Parkinson ’ s Disease (2001) (18)
- Pharmacology of Parkinson's disease. (1984) (18)
- Is the neuropathological 'gold standard' diagnosis dead? Implications of clinicopathological findings in an autosomal dominant neurodegenerative disorder. (2004) (18)
- ANALYSIS OF [3H]NEUROTENSIN RECEPTORS BY COMPUTERIZED DENSITOMETRY: VISUALIZATION OF CENTRAL AND PERIPHERAL NEUROTENSIN RECEPTORS (1982) (17)
- Clinical relevance of dopamine receptor classification (1980) (17)
- Studies of parkinsonian movement: 2. Initiation of fast voluntary eye movement during postural disturbance (1980) (17)
- I‐Dopa in the treatment of parkinsonism (1970) (17)
- Cross tolerance between two dopaminergic ergot derivatives--bromocriptine and lergotrile. (1980) (17)
- Neurotoxins and degeneration in the central nervous system. (1991) (17)
- Hepatocellular injury with distinctive mitochondrial changes induced by lergotrile mesylate: a dopaminergic ergot derivative. (1979) (17)
- The role of the Lewy body in idiopathic Parkinsonism. (1998) (16)
- Penicillin transport from cerebrospinal fluid (1976) (16)
- Citation of original research (1992) (16)
- Lisuride and Other Dopamine Agonists: Basic Mechanisms and Endocrine and Neurological Effects (1982) (16)
- Functional imaging in Tourette’s syndrome (2004) (15)
- Dopamine receptors in movement disorders (1981) (15)
- Dopamine agonists and Parkinson's disease (1984) (15)
- Current Views on Parkinson’s Disease (1983) (15)
- [Hereditary Parkinson disease: report of 3 families with dominant autosomal inheritance]. (1993) (15)
- The nature of Parkinson's disease (1992) (15)
- Advances in the neuropharmacology of Parkinsonism. (1979) (14)
- Action of Thymoxamine on Mydriasis induced by Levodopa and Dopamine (1971) (13)
- Sinemet in Parkinson's disease: efficacy with and without food. (1986) (13)
- Parkinson's disease, motoneuron disease and Alzheimer's disease: origins and interrelationship. (1990) (13)
- Theories of Neurodegeneration (1992) (13)
- Nomifensine in parkinsonism. (1977) (13)
- Positron emission tomography in Shy‐Drager syndrome (1990) (13)
- Disposition of oral lisuride in parkinson's disease (1984) (12)
- Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism. (1975) (12)
- Parkinsonism and Related Disorders: Looking back over twenty years (2015) (12)
- The Role of Various Forms of Treatment in the Management of Parkinson's Disease (1982) (11)
- Chapter 9: Dopaminergic Agonists in the Treatment of Parkinsonism (1978) (11)
- Dystonia: treatment with bromocriptine. (1985) (11)
- Recent advances in the study of Parkinson's disease (1982) (11)
- Arterial blood pressure in patients with Parkinson's disease (1975) (11)
- Dementia in Parkinson's disease (1986) (11)
- Normality and Disease (1988) (11)
- Positron emission tomography of dopamine pathways in familial Parkinsonian syndromes. (2001) (10)
- Recent advances in the treatment of Parkinson's disease: The role of bromocriptine (2005) (10)
- Examination of the presynaptic dopaminergic system using positron emission tomography in a famly with autosomal dominant parkinsonism and dementia due to pallido-ponto-nigral degeneration (PPNO) (1993) (10)
- Dopa‐responsive dystonia (1994) (10)
- Botulinum toxin in cervical dystonia. (1988) (9)
- Tendon jerks in Parkinson's disease (1994) (9)
- Parkinsonism: Its Relation to Aging and Its Treatment (1979) (9)
- Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies. (1983) (9)
- Clinical heterogeneity of dopa-responsive dystonia: PET observations. (1993) (9)
- Dementia with Lewy Bodies: What do Lewy bodies tell us about dementia and parkinsonism? (1996) (9)
- Manganese-Induced Neurotoxicity (1994) (9)
- Current concepts on the etiology of Parkinson's disease (1989) (9)
- Gout induced by L-dopa and decarboxylase inhibitors (1976) (9)
- Controversies in the management of Parkinson's disease (1986) (9)
- Treatment of refractory Parkinson's disease with adrenal medullary autografts utilizing two-stage surgery. (1990) (9)
- Essential tremor. (1983) (8)
- Pathophysiology and pharmacotherapy of tremor (1977) (8)
- Dopaminergic agonists in Parkinsonism. (1975) (8)
- Animal models of parkinsonism. (1981) (8)
- Therapeutics in neurology (1975) (8)
- Ergot Derivatives for Parkinsonism (1978) (8)
- Metabolic studies with bromocriptine in patients with idiopathic parkinsonism and Huntington's chorea. (1976) (8)
- Parkinsonism and cardiac arrhythmias. (1970) (8)
- PET imaging in Parkinsonism. (1993) (8)
- A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys (1988) (8)
- Initiating treatment for idiopathic parkinsonism. (1994) (8)
- DOPAMINERGIC ERGOTS: DRUGS WHICH DISCRIMINATE BETWEEN THE MULTIPLE CLASSES OF DOPAMINE RECEPTORS (1979) (7)
- Dementia in Movement Disorders (1986) (7)
- A reassessment of the Lewy body. (2005) (7)
- Treatment for the progression of Parkinson's disease (2005) (7)
- Parkinson's disease (1985) (7)
- Potential Therapeutic Uses of Dopamine Receptor Agonists and Antagonists (1983) (6)
- Patent ductus arteriosus in an elderly man. (1966) (6)
- Deprenyl and the issue of neuroprotection. (1994) (6)
- Sympathetic skin response and RR interval variation in manganism and a comparison with Parkinson's disease. (1996) (6)
- Diagnosis and management of Parkinson's disease. (1984) (6)
- Individualizing therapy in patients with disabling Parkinson's disease symptoms (1994) (6)
- Altered hypothermic responsiveness to (+)‐amphetamine (1976) (6)
- Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease. (1999) (6)
- Effect of sodium valproate on parkinsonism and L-DOPA induced dyskinesia (1980) (6)
- Miosis during L-Dopa Therapy (1970) (6)
- Incontinence of urine with long‐term bromocriptine therapy (1980) (6)
- Tremor induced by tetrabenazine (1969) (6)
- Early idiopathic parkinsonism: initiation and optimization of treatment. (1994) (6)
- Role of ergot derivatives in the treatment of parkinsonism. (1978) (6)
- PET scan study on the dopaminergic system in a Japanese patient with hereditary progressive dystonia (Segawa's disease). Case report. (1993) (6)
- Dopamine Receptor Agonists in the Treatment of Basal Ganglia Disorders (1982) (6)
- Developments in the treatment of parkinsonism. (1976) (6)
- Autosomal dominant forms of hereditary hypertrophic neuropathy. (1972) (5)
- Sodium Valproate in the Treatment of Cerebellar Disorders (1979) (5)
- NORMAL AGING OF THE NERVOUS SYSTEM. REPLIES (1992) (5)
- Pharmacological Treatment of Parkinson’s Disease (1986) (5)
- Early parkinsonism. (1986) (5)
- [Comparison study of positron emission tomography, X-ray CT and MRI in parkinsonism with dementia]. (1989) (5)
- L-DOPA effect on blood pressure in man. (1977) (5)
- Effect of antacid on levodopa therapy. (1986) (5)
- Pimozide in tardive dyskinesia. (1974) (4)
- Circulatory effects of intravenous tyramine and noradrenalin in Parkinsonism. (1972) (4)
- Symposium I: Therapeutic controversies in movement disorders. (1979) (4)
- Relationship of plasma concentrations of levodopa to clinical response in Parkinsonsim. (1971) (4)
- DCTN1 mutations in families with parkinsonism, depression, weight loss and central hypoventilation: Perry syndrome (2008) (4)
- Parkinson’s Disease: Where Are We? (2004) (4)
- Clinical Trials for Parkinson’s Disease (1989) (4)
- Fluorodopa PET Scans of Juvenile Parkinsonism with Prominent Dystonia in Relation to Dopa-Responsive Dystonia1 (1995) (4)
- Developments in understanding the physiology and pharmacology of parkinsonism (1979) (4)
- Prospects for new drug treatment in idiopathic parkinsonism (1998) (3)
- Parkinson's disease. (1989) (3)
- Transmitter receptor alterations in Parkinson's disease. (1987) (3)
- Treatment of parkinsonism. (1977) (3)
- Efficacy of dopamine agonists in dystonia. (1988) (3)
- Decreased efficacy of levodopa with carbidopa in parkinsonian patients after adrenal‐to‐caudate implants (1990) (3)
- OXPRENOLOL AND LEVODOPA IN PARKINSONIAN PATIENTS (1975) (3)
- Parametric imaging of the rate constant Ki using [18Fluoro]-l-dopa positron emission tomography in progressive supranuclear palsy (2004) (3)
- Parkinson's disease over the last 100 years. (2003) (3)
- Motornerveconduction velocity inperoneal muscular atrophy: evidence forgenetic heterogeneity (1974) (3)
- The pathogensis and medical treatment of extrapyramidal disease. (1979) (3)
- Lisuride in parkinsonism (1981) (3)
- What is it? Case 1, 1988. Head tilt in a young girl associated with neck pain and limitation of neck movement (1988) (3)
- Oligoclonal banding inthecerebrospinal fluid of patients withpostencephalitic Parkinsonism (1979) (2)
- Cardiovascular reflex activity in Parkinsonism. (1971) (2)
- Therapeutic manipulation of excitatory amino acid systems (1994) (2)
- [L-18F-dopa-PET in Parkinson-plus syndromes for the detection of a disordered presynaptic dopaminergic function]. (1992) (2)
- Progress in the pharmacotherapy of Parkinsonism. (1980) (2)
- Lettre de M. Ie Professeur J. Talairach à la «World Society for Stereotactic and Functional Neurosurgery» (1985) (2)
- New Perspectives in Parkinson’s Disease (1987) (2)
- Cranial herpes zoster: a case report and a hypothesis. (1980) (2)
- Tissue Transplantation for Parkinson's Disease (1988) (2)
- Parkinson’s Disease: Clinical Trials (1986) (2)
- National Conference on Parkinson's Disease (1991) (2)
- CF 25 397 in Parkinsonism (1977) (1)
- Options for the etiology of Parkinson's disease: the association with dementia. (1988) (1)
- CURRENT APPROACHES TO PARKINSONISM (1979) (1)
- Letter: Oxprenolol and levodopa in parkinsonian patients. (1975) (1)
- Hypotension after exercise. (1966) (1)
- Assessment of hypokinesia in parkinsonism (2005) (1)
- Advances in Research on Neurodegeneration (2000) (1)
- Altered Facilitation of Cortical Motor Evoked Potentials in Parkinson??s Disease (1988) (1)
- Glutamate and epilepsy : theories and therapeutics (1994) (1)
- Mesulergine for parkinsons disease a comparison with bromocriptine (1984) (1)
- The effects of dopamine, L-dopa, L-tyrosine, and pyridoxine on sympathetic nerve endings in man. (1970) (1)
- Intravenous Treatment With Levodopa After Major Abdominal Surgery (2017) (1)
- Degenerative diseases in the CNS (1998) (1)
- Drug treatment of spasticity and rigidity. (1975) (1)
- THE HEPATOTOXICITY OF ERGOT ALKALOIDS (1979) (1)
- Transcranial magnetic stimulation in aging and degenerative disease of the nervous system (1990) (1)
- LRRK2 (Leucine-Rich Repeat Kinase 2) Gene on PARK8 Locus in Families with Parkinsonism (2008) (1)
- Examination of the time relations of electrical activity in different muscle groups during tremor. (1968) (1)
- Genetic linkage studies in autosomal dominantly inherited L-DOPA responsive parkinsonism. Evaluation of candidate genes. (1996) (1)
- Evaluation of Parkinson’s Disease (1989) (1)
- Motor function in the norimal aging population (1985) (1)
- Augmenting the action of levodopa (1972) (1)
- MOTOR AREAS OF THE CEREBRAL-CORTEX - FINAL GENERAL DISCUSSION (1987) (0)
- Treatment of Parkinsonian Features in Neurological Disorders Other than Parkinson's Disease (1989) (0)
- Immunohistochemical Features which Distinguish Pallido‐Nigro‐Luysial Atrophy from Progressive Supranuclear Palsy (1994) (0)
- Dr. Calne responds. (1989) (0)
- Positron emission tomography and histopathology in Pickʼs disease (1987) (0)
- Strategies for treating complications of levodopa therapy (1994) (0)
- Pharmacotherapy and Treatment of Parkinson's Disease (2007) (0)
- I Recen t Advances in Pharmacotherapy Parkinson's disease (2005) (0)
- Tremor (1972) (0)
- Progressive supranuclear palsy as a cause of balance disorders. (2003) (0)
- 24 – Transplantation of Human Sympathetic Neurons and Adrenal Chromaffin Cells into Parkinsonian Monkeys (1991) (0)
- ARTERIAL BLOOD PRESSURE IN VARIOUS SUB-GROUPS OF PATIENTS WITH PARKINSONISM (0)
- Antiparkinsonian therapy. (1977) (0)
- The nature of Pakinson's disease (1992) (0)
- 2.012 Perry's syndrome is a unique TDP-43 proteinopathy (2007) (0)
- Deprenyl in Parkinson disease (1981) (0)
- In Memoriam / Title Page / Table of Contents (1985) (0)
- Book Review: Alzheimer's Disease and Related Conditions (1971) (0)
- Reply (1992) (0)
- Changes in baroreflexes induced by L-dopa. (1972) (0)
- Synthetic dopamine agonists (2002) (0)
- Parkinsonian Syndrome and the Definition of Parkinson's Disease (2002) (0)
- Reproducibility Studies with ‘1C-DTBZ, a Monoamine Vesicular TransporterInhibitorin Healthy Human Subjects (1999) (0)
- I.1 The problem of dementia in Parkinson's Disease (2006) (0)
- PLATELET NEUROTRANSMITTER – RELATED ENZYMES IN PSYCHO – PHARMACOLOGIC STUDIES (1981) (0)
- GABA-ergic systems in parkinsonism (1979) (0)
- Books Received (2001) (0)
- Altered hypothermic responsivness to (+)-amphetamine. (1976) (0)
- HANDBOOK OF PARKINSON'S DISEASE. Edited by William C. Koller. Published by Marcel Dekker, Inc. 520 pages. (1988) (0)
- Parkinson's disease: unanswered questions. (1980) (0)
- L-18F-DOPA PET for the Assessment of Disturbed Nigrostriatal Function in Parkinsonism-Plus Syndromes (1992) (0)
- SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia (2013) (0)
- Clinical studies with bromocriptine in idiopathic parkinsonism. (1976) (0)
- Tics and Related Disorders. By A.J. Lees. Published by Churchill-Livingstone (Academic Press Canada). 276 pages. Cdn. $72.00 approx. (1987) (0)
- Need for uncombined carbidopa to treat parkinsonism (1978) (0)
- 1st Sandoz Symposium on the Treatment of Parkinson’s Disease, Vol. 33(suppl 1), 1993 (1993) (0)
- Progress in the Treatment of Parkinson’s Disease (2002) (0)
- tomography in patients With clinically diagnosed Alzhelmer s disease (2006) (0)
- Summary and Concluding Remarks (1987) (0)
- emission tomography . Wilson ' s disease studied with positron The nigrostriatal dopaminergic pathway in (0)
- Reply (1993) (0)
- Chapter 2: Treatment of Epilepsy With Valproate (1979) (0)
- 2.115 Perry's syndrome is a unique TDP-43 proteinopathy (2007) (0)
- Action of levodopa on the blood pressure of conscious rabbits. (1973) (0)
- Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500,288 Single-Nucleotide Polymorphisms (2007) (0)
- Reply (1992) (0)
- Discussion: Session 5 — 8 P.M. - 9 February 1993 (1994) (0)
- The mechanism and management of headache (1970) (0)
- Cranial herpes zoster : a case report (0)
- Arterial blood pressureinpatients with Parkinson's disease (1975) (0)
- General Discussion of Part III (1988) (0)
- Cerebral Glucose Metabolism in the ALS-PD Complex of Guam (1987) (0)
- The Authors Respond (1994) (0)
- The pharmacology of extrapyramidal movement disorders (monographs in neural sciences, vol. 2) (1974) (0)
- Huntington Chorea-Reply (1977) (0)
- L-Dopa and Parkinsonism. (1970) (0)
- Reply (1994) (0)
- Dopaminergic Agonists and Receptors: Their Relevance to the Treatment of Parkinson’s Disease (1985) (0)
- Summary of the Letter of Prof. J. Talairach Read by Dr. Munari to the World Congress of the World Society for Stereotactic and Functional Neurosurgery (1985) (0)
- Hypotension CausedbyL-Dopa (1970) (0)
- Reply (1990) (0)
- New approaches to old diseases (1987) (0)
- Author/Subject Indexes (1993) (0)
- Reply (1992) (0)
- The Twin Hemispheres (1973) (0)
- Authors' Reply (1987) (0)
- TREATMENT OF SPASTICITY WITH BOTULINUM TOXIN. AUTHOR'S REPLIES (1992) (0)
- Parkinson's disease over the last 20 years: a personal view. (1988) (0)
- Augmenting theaction oflevodopa (1972) (0)
- LibriAdvances in Research on Neurodegeneration, Volume 3 & 4, Springer Verlag, Boston/Dordrecht/London (1997) (1998) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Donald Brian Calne?
Donald Brian Calne is affiliated with the following schools:
